RGLS Regulus Therapeutics Inc.

1.45
+0  (4%)
Previous Close 1.40
Open 1.40
Price To book 1.32
Market Cap 76.75M
Shares 52,932,000
Volume 351,101
Short Ratio 3.17
Av. Daily Volume 1,159,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 4Q 2017.
RG-012
Renal biopsy study in Alport patients
Phase 2 interim data due mid-2018.
RG-012 - HERA
Alport Syndrome
Clinical hold placed June 2016. Announced January 27, 2017 that clinical hold remains in place.
RG-101 and GSK2878175 - randomized
Hepatitis C virus (HCV)
Clinical hold placed June 2016. Announced January 27, 2017 that clinical hold remains in place.
RG-101 with multiple approved DAAs
Hepatitis C virus (HCV)
Clinical hold placed June 2016. Announced January 27, 2017 that clinical hold remains in place.
RG-101 and GSK2878175 open label
HCV

Latest News

  1. DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  2. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Regulus Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline
  3. DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
  4. RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017
  5. DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline
  7. DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
  8. IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  9. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline - April 3, 2017
  10. IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm
  11. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017
  12. Regulus to Present at the 16th Annual Needham Healthcare Conference
  13. SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm
  14. Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017
  16. INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
  17. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017
  18. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm